KPT-9274

DRUG2 trials

Sponsors

Karyopharm Therapeutics Inc, University of Colorado, Denver

Conditions

Acute Myeloid LeukemiaAcute Myeloid Leukemia RefractoryAcute Myeloid Leukemia, in RelapseNHLSolid Tumors

Phase 1

PAK4 and NAMPT in Patients With Solid Malignancies or NHL (PANAMA)

TerminatedNCT02702492

Karyopharm Therapeutics IncNHL, Solid Tumors

Start: 2016-06-08End: 2021-01-26Updated: 2024-11-25

KPT-9274 in Patients With Relapsed and Refractory Acute Myeloid Leukemia

CompletedNCT04914845

University of Colorado, DenverAcute Myeloid Leukemia, Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory

Start: 2021-08-27End: 2025-10-22Updated: 2026-01-27

Related Papers

First-in-Human Phase I Study of KPT-9274, a First-in-Class Dual Inhibitor of PAK4 and NAMPT, in Patients with Advanced Solid Malignancies

Targeted Oncology2026-03-13

Identification of Nuclear NAD+ Salvage As a Therapeutic Vulnerability in B-Lymphoid Malignancies

Blood2024-11-05

<i>NAMPT</i> Haploinsufficiency Is a Therapeutic Vulnerability in High-Risk Myeloid Malignancies

Blood2023-11-021 citations

Computational Discovery and Validation of NAD+ Biosynthesis As Unique Vulnerability in B-Lymphoid Malignancies

Blood2023-11-02

Dual Targeting PAK4 and NAMPT As a Novel Therapeutic Approach for Aggressive Non-Hodgkin's Lymphoma

Blood2021-11-05

Abstract 4368: PAK4-NAMPT dual inhibition as a feasible strategy for treatment of resistant pancreatic neuroendocrine tumors

Cancer Research2018-07-01

EXTH-84. TARGETING THE SALVAGE PATHWAY OF NAD+ GENERATION IN GLIOMAS BY KPT-9274, A NOVEL DUAL INHIBITOR OF PAK4 AND NAMPT

Neuro-Oncology2017-11-01

Abstract LB-308: KPT-9274 inhibits cellular NAD and synergizes with doxorubicin to treat dogs with lymphoma

Cancer Research2017-07-015 citations

Novel p21-Activated Kinase 4 (PAK4) Allosteric Modulators Overcome Drug Resistance and Stemness in Pancreatic Ductal Adenocarcinoma

Molecular Cancer Therapeutics2016-11-1687 citations